Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02393248 · ClinicalTrials.gov registry record · Phase 1
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 201
- Enrollment target
NCT02393248 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 201 participants.
The verdict
NCT02393248, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 201 participants
- Enrollment target
Study Summary
The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies. This study will have three parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).
Interventions
- DRUG Pembrolizumab
- DRUG Trastuzumab
- DRUG Docetaxel
- DRUG Gemcitabine
- DRUG Pemigatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2015-02-27 |
| Est. Completion | 2021-12-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02393248
The ClinicalTrials.gov registry entry for NCT02393248 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT02393248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02393248 about?
NCT02393248 is a clinical study titled "Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)". The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies. This study will have three parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).
What is the current status of trial NCT02393248?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 201 participants. The study started on 2015-02-27. Estimated completion is 2021-12-17.
What interventions are being tested in trial NCT02393248?
The interventions under investigation include: Pembrolizumab (DRUG), Trastuzumab (DRUG), Docetaxel (DRUG), Gemcitabine (DRUG), Pemigatinib (DRUG).
Who is sponsoring clinical trial NCT02393248?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.